This Notice of Allowance is a continuation of AXIM’s patent (US 10,092,538 B2) granted to the Company in October 2018.
Read More
This new patent, which expires in 2038, is part of an expanding intellectual property portfolio.
Read More
The Company expects to report topline results from this study in the summer of 2020. These data are anticipated to support an initial marketing application for lenabasum.
Read More
The cannabis extract research and development targets four specific health issues: Chronic Obstructive Pulmonary Disease (COPD); Type 2 Diabetes; Cancer Pain Management, and Epilepsy.
Read More
Both products are chewing gums containing synthetic tetrahydrocannabinol (THC) and cannabidiol (CBD) respectively, and utilize the company’s patented chewing gum delivery mechanism.
Read More
Get stock alerts, news & related alerts straight to your inbox!